{"id":"arbekacin","rwe":[{"pmid":"41431648","year":"2025","title":"A systematic review of the role of methylase genes in antibiotic resistance: co-existence with extended spectrum β-lactamase and carbapenemase genes in Klebsiella pneumoniae.","finding":"","journal":"PeerJ","studyType":"Clinical Study"},{"pmid":"41340921","year":"2026","title":"Total syntheses of ent-aogacillin A and aogacillin B.","finding":"","journal":"Chemical science","studyType":"Clinical Study"},{"pmid":"41282956","year":"2025","title":"Drug repurposing for type 2 diabetes: computational studies of potential alpha-glucosidase inhibitors from DrugBank.","finding":"","journal":"In silico pharmacology","studyType":"Clinical Study"},{"pmid":"40415027","year":"2025","title":"Structure-function comparison of Arbekacin with other aminoglycosides elucidates its higher potency as bacterial translation inhibitor.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"38343924","year":"2024","title":"Experimental Determination of the pK(a) Values of Clinically Relevant Aminoglycoside Antibiotics: Toward Establishing pK(a)-Activity Relationships.","finding":"","journal":"ACS omega","studyType":"Clinical Study"}],"tags":[{"label":"arbekacin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01GB12","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"habekacin","offLabel":[],"synonyms":["arbekacin","AHB-DKB","HABA-DKB","habekacin"],"timeline":[],"brandName":"Habekacin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"arbekacin","explanation":"Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Arbekacin stops these bacterial factories from working by blocking the production of essential proteins, which ultimately kills the bacteria.","oneSentence":"Arbekacin works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.","technicalDetail":"Arbekacin exerts its antibacterial effects by binding to the 30S subunit of the bacterial ribosome, thereby inhibiting the initiation of protein synthesis and preventing the production of essential proteins necessary for bacterial survival and proliferation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/235","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ARBEKACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARBEKACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:49:19.679372","biosimilars":[],"competitors":[{"drugName":"tobramycin","drugSlug":"tobramycin","fdaApproval":"1975-06-11","patentExpiry":"Sep 12, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gentamicin","drugSlug":"gentamicin","fdaApproval":"1970-06-19","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"kanamycin","drugSlug":"kanamycin","fdaApproval":"1973-02-13","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amikacin","drugSlug":"amikacin","fdaApproval":"1981-01-22","patentExpiry":"May 15, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"netilmicin","drugSlug":"netilmicin","fdaApproval":"1983-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plazomicin","drugSlug":"plazomicin","fdaApproval":"2018-06-25","patentExpiry":"Nov 21, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"arbekacin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tobramycin","brandName":"tobramycin","genericName":"tobramycin","approvalYear":"1975","relationship":"same-class"},{"drugId":"gentamicin","brandName":"gentamicin","genericName":"gentamicin","approvalYear":"1970","relationship":"same-class"},{"drugId":"kanamycin","brandName":"kanamycin","genericName":"kanamycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"amikacin","brandName":"amikacin","genericName":"amikacin","approvalYear":"1981","relationship":"same-class"},{"drugId":"netilmicin","brandName":"netilmicin","genericName":"netilmicin","approvalYear":"1983","relationship":"same-class"},{"drugId":"plazomicin","brandName":"plazomicin","genericName":"plazomicin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01659515","phase":"","title":"Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria","status":"NO_LONGER_AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":["Infection Due to Resistant Organism"],"enrollment":0,"completionDate":""},{"nctId":"NCT02459158","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2015-09","conditions":["Pneumonia, Bacterial"],"enrollment":25,"completionDate":"2017-03-22"},{"nctId":"NCT01918384","phase":"PHASE2","title":"Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2013-08","conditions":["Muscular Dystrophy, Duchenne"],"enrollment":21,"completionDate":"2015-10"},{"nctId":"NCT01907776","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2013-07","conditions":["Healthy"],"enrollment":56,"completionDate":""},{"nctId":"NCT01961830","phase":"PHASE1","title":"Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2013-09","conditions":["Healthy"],"enrollment":42,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007488","UNII":"G7V6SLI20L","CHEBI":"CHEBI:37922","INN_ID":"5914","RXNORM":"26397","UMLSCUI":"C1148057","ChEMBL_ID":"CHEMBL426926","KEGG_DRUG":"D07462","DRUGBANK_ID":"DB06696","PDB_CHEM_ID":" 84G","PUBCHEM_CID":"68682","SNOMEDCT_US":"725569009","IUPHAR_LIGAND_ID":"7345","MESH_SUPPLEMENTAL_RECORD_UI":"C031986"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.46 hours","clearance":"1.28 mL/min/kg","bioavailability":"0%","volumeOfDistribution":"0.21 L/kg"},"publicationCount":433,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01GB12","allCodes":["J01GB12"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41431648","title":"A systematic review of the role of methylase genes in antibiotic resistance: co-existence with extended spectrum β-lactamase and carbapenemase genes in Klebsiella pneumoniae.","journal":"PeerJ"},{"date":"2026 Jan 28","pmid":"41340921","title":"Total syntheses of ent-aogacillin A and aogacillin B.","journal":"Chemical science"},{"date":"2025","pmid":"41282956","title":"Drug repurposing for type 2 diabetes: computational studies of potential alpha-glucosidase inhibitors from DrugBank.","journal":"In silico pharmacology"},{"date":"2025 May 25","pmid":"40415027","title":"Structure-function comparison of Arbekacin with other aminoglycosides elucidates its higher potency as bacterial translation inhibitor.","journal":"Scientific reports"},{"date":"2024 Feb 6","pmid":"38343924","title":"Experimental Determination of the pK(a) Values of Clinically Relevant Aminoglycoside Antibiotics: Toward Establishing pK(a)-Activity Relationships.","journal":"ACS omega"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arbekacin, also known as Habekacin, is a small molecule antibiotic in the arbekacin class. It is used to treat bacterial infections, although its specific target and approved indications are unknown. The commercial status of arbekacin is unclear, and it may be patented or available as a generic medication. Key safety considerations include its low bioavailability and short half-life of 2.46 hours. Further research is needed to fully understand the pharmacology and clinical use of arbekacin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}